Skip to main content
Clinical Trials/NCT02576002
NCT02576002
Completed
Not Applicable

Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US

Bayer0 sites2,691 target enrollmentOctober 2015

Overview

Phase
Not Applicable
Intervention
Assigned pulmonary hypertension medication
Conditions
Hypertension, Pulmonary
Sponsor
Bayer
Enrollment
2691
Primary Endpoint
Incidence rate of PAH (pulmonary arterial hypertension)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013

Registry
clinicaltrials.gov
Start Date
October 2015
End Date
January 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All PAH patients who were in the MarketScan database and who were under age 18 at some time during the years 2010 through 2013

Exclusion Criteria

  • Not applicable

Arms & Interventions

Pediatric PAH patients

US pediatric population with PAH in MarketScan database during the period 2010-2013

Intervention: Assigned pulmonary hypertension medication

Outcomes

Primary Outcomes

Incidence rate of PAH (pulmonary arterial hypertension)

Time Frame: Retrospective analysis of three year period

Prevalence rate of PAH

Time Frame: Retrospective analysis of three year period

Secondary Outcomes

  • Assigned drug treatment for PAH measured using the MarketScan database(Retrospective analysis of three year period)
  • Diagnostic procedures performed among PAH patients measured using the MarketScan database(Retrospective analysis of three year period)
  • Prevalence of comorbidities among PAH patients(Retrospective analysis of three year period)

Similar Trials